SCHEMBL3733019

SCHEMBL3733019

O=c1ccc2ccccc2n1NCCC1CCCCN1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.44
CYP2D6 P10635 2/20 0.44
CYP2C19 P33261 2/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C9 P11712 1/20 0.44
KMT2A Q03164 1/20 0.41
POLB P06746 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
HIF1A Q16665 1/20 0.38
PHLPP2 Q6ZVD8 1/20 0.38
NPY1R P25929 2/20 0.37
PRKACA P17612 1/20 0.37
PRKACG P22612 1/20 0.37
PRKACB P22694 1/20 0.37
CAMK2D Q13557 1/20 0.37
HTR1A P08908 1/20 0.37
HTR1D P28221 1/20 0.37
HTR2A P28223 1/20 0.37
HRH1 P35367 1/20 0.37
ADRA1B P35368 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1054061 0.88 CYP1A2 (0.41) CYP1A2CYP2D6CYP2C19CYP3A4CYP2C9
SCHEMBL1052083 0.84 POLR1A (0.38) CYP1A2CYP2D6CYP2C19CYP3A4CYP2C9
SCHEMBL1055040 0.84 POLR1A (0.38) CYP1A2CYP2D6CYP2C19CYP3A4CYP2C9
SCHEMBL1054633 0.84 POLR1A (0.38) CYP1A2CYP2D6CYP2C19CYP3A4CYP2C9
SCHEMBL1054247 0.73 EPHX1 (0.41) KMT2APOLBSMN1; SMN2
SCHEMBL1052583 0.73 KAT2B (0.42) KMT2APOLBSMN1; SMN2
SCHEMBL3738350 0.72 KAT2B (0.41) KMT2APOLBSMN1; SMN2
SCHEMBL1049828 0.71 HTR4 (0.45) KCNH2
SCHEMBL3733975 0.70 CA12 (0.49) CYP1A2CYP2C19CYP3A4KMT2A
SCHEMBL6436320 0.70 CA12 (0.49) KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825132-B2 Inhibition of FGFR3 and treatment of multiple myeloma NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-11-02 US disclosed